Friesen Lynn R, Goyal C R, Qaqish Jimmy G, He Tao, Eusebio Rachelle, Zsiska Marianne, Farmer Teresa, Schneiderman Eva
University of Kansas City-Missouri School of Dentistry, Kansas City, MO, USA.
All Sum Research, Mississauga, Ontario, Canada.
J Clin Dent. 2017 Dec;28(4 Spec No B):B6-11.
To compare the effect of a stannous fluoride dentifrice versus a triclosan-containing dentifrice on the reduction of plaque using in vitro and clinical models.
Both investigations evaluated a novel 0.454% stabilized stannous fluoride dentifrice (Crest® Pro-Health™ smooth formula) versus a sodium fluoride/triclosan positive control dentifrice (Colgate® Total®). The in vitro evaluation utilized the Plaque Glycolysis and Regrowth Model (PGRM), wherein the metabolic effects (acid production/glycolysis inhibition) of the dentifrices were assessed on plaque biofilms grown on glass rods after three days growth and a single dentifrice treatment. Treatments were evaluated via analysis of variance, Student's t-test. The clinical trial was a four-week, single-center, randomized and controlled, double-blind, parallel group study, where 120 adults were randomized to one of the two dentifrices for use at home according to manufacturer's instructions. Plaque was evaluated at baseline and Week 4 with the Rustogi Modified Navy Plaque Index (RMNPI). Statistical analyses were via analysis of covariance.
In vitro PGRM: The stannous fluoride dentifrice provided 43.3% glycolysis inhibition compared to 27.5% for the triclosan control, and the pH decrease associated with acid production was significantly less for stannous fluoride (0.87) versus triclosan (1.11); p < 0.05. Clinical trial: One hundred eighteen (118) subjects completed the study with fully evaluable data. Both dentifrice groups demonstrated statistically significant (p < 0.0001) reductions in plaque at Week 4 compared with baseline, with the stannous fluoride dentifrice producing a significantly lower adjusted mean Week 4 plaque score (p < 0.0001) versus the triclosan positive control for whole mouth plaque (23.1% lower) and interproximal plaque (43.5% lower). Both dentifrices were well-tolerated.
The stabilized stannous fluoride dentifrice provided statistically significant reductions in plaque glycolysis in vitro and plaque growth in vivo compared to the triclosan dentifrice. Results for both studies were consistent.
使用体外和临床模型比较含氟化亚锡牙膏与含三氯生牙膏在减少牙菌斑方面的效果。
两项研究均评估了一种新型的0.454%稳定化氟化亚锡牙膏（佳洁士®专业健康™柔滑配方）与一种氟化钠/三氯生阳性对照牙膏（高露洁®全效®）。体外评估采用菌斑糖酵解和再生长模型（PGRM），即在玻璃棒上生长三天并经单次牙膏处理后，评估牙膏对菌斑生物膜的代谢作用（产酸/糖酵解抑制）。通过方差分析、学生t检验对处理进行评估。临床试验是一项为期四周的单中心、随机对照、双盲、平行组研究，120名成年人根据制造商说明被随机分配至两种牙膏之一在家中使用。在基线和第4周时用Rustogi改良海军菌斑指数（RMNPI）评估牙菌斑。通过协方差分析进行统计分析。
体外PGRM：氟化亚锡牙膏的糖酵解抑制率为43.3%，而三氯生对照牙膏为27.5%，且与产酸相关的pH值下降在氟化亚锡牙膏（0.87）中明显低于三氯生牙膏（1.11）；p<0.05。临床试验：118名受试者完成了具有完全可评估数据的研究。与基线相比，在第4周时两个牙膏组的牙菌斑均有统计学意义的显著减少（p<0.0001），与三氯生阳性对照相比，氟化亚锡牙膏在第4周时产生的调整后平均牙菌斑评分显著更低（p<0.0001），全口牙菌斑（低23.1%）和邻面牙菌斑（低43.5%）。两种牙膏耐受性均良好。
与含三氯生牙膏相比，稳定化氟化亚锡牙膏在体外可使菌斑糖酵解及在体内可使菌斑生长有统计学意义的显著减少。两项研究结果一致。
